Frank Sinicrope, Clinical Investigator of the Mayo Foundation and Co-leader GI Cancer Program at Mayo Clinic Rochester, shared a post on X:
“For dMMR colon cancer, FOLFOX + atezolizumab per ATOMIC is now incorporated into the NCCN Guidelines.”
More posts featuring Frank Sinicrope.